Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL)
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 1 July 2026 | Viewed by 2294

Special Issue Editor

Dr. Erel Joffe

E-Mail Website
Guest Editor
Lymphoma Service, Department of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel
Interests: genome-phenotype association studies in lymphoma; machine learning; natural language processing; clinical trials

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to a Special Issue on “Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL)” for Cancers. Diffuse large B cell lymphoma (DLBCL) remains a significant challenge in hematologic oncology, despite recent advances in treatment modalities. Clinical trials are at the forefront of developing new therapies and treatment strategies, making them crucial for improving outcomes for DLBCL patients. This Special Issue aims to explore and highlight the latest developments in DLBCL clinical trials, fostering a deeper understanding of current research and future directions in this critical field.

This Special Issue aims to provide an overview of cutting-edge clinical trials that are reshaping our approach to the management of DLBCL. In this Special Issue, original research articles and reviews are welcome. We accept studies showing meaningful but negative results. Research areas may include (but are not limited to) the following:

  1. Sequencing treatment regimens with novel immunotherapies.
  2. Novel drug combinations and their efficacy and side effect profiles.
  3. New paradigms for the incorporation of radiotherapy.
  4. Management of emerging side effects from novel therapies (with a particular focus on prolonged cytopenias, cognitive changes, immunosuppression and associated infections).
  5. Treatment paradigms for underserved subtypes of DLBCL (e.g., primary CNS lymphoma, primary vitreo-retinal lymphoma, transformed marginal zone lymphoma, Richter’s syndrome).
  6. Use of novel therapies in elderly patients.
  7. Integration of novel diagnostic tests (e.g., ctDNA) in treatment decisions.
  8. Use of novel biomarkers for treatment selection and personalized medicine approaches.
  9. Challenges in clinical trial management, including administrative burdens and updated good clinical practice guidelines.
  10. Applications of novel computational tools and artificial intelligence in clinical trial management.

We look forward to receiving your contributions to this important Special Issue.

Dr. Erel Joffe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • DLBCL
  • immunotherapy
  • drug combinations
  • elderly patients
  • ctDNA
  • biomarkers
  • radiotherapy
  • clinical trial management
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1168 KB  
Article
Real-World Data of R-mini-CHOP Therapy in Elderly Hispanic Population with Diffuse Large B-Cell Lymphoma and High-Grade Follicular Lymphoma
by Carla Romagnoli, Veronica Guerra, Leily Santos-Carrion, Marisol Ocampo, Alexandra Lyubimova, Evelyn Goya Balaguer, Yelida Brauchle, Oleg Gligich, Bruno Bastos, Aron Simkins, Arnold Blaustein, Michael Schwartz, Mike Cusnir and Jacqueline C. Barrientos
Cancers 2026, 18(7), 1124; https://doi.org/10.3390/cancers18071124 - 31 Mar 2026
Viewed by 849
Abstract
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) are aggressive B-cell malignancies predominantly affecting older adults. R-CHOP remains the frontline standard of care, with frail and elderly patients requiring attenuated regimens such as R-mini-CHOP. Real-world comparative data in elderly [...] Read more.
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) are aggressive B-cell malignancies predominantly affecting older adults. R-CHOP remains the frontline standard of care, with frail and elderly patients requiring attenuated regimens such as R-mini-CHOP. Real-world comparative data in elderly and Hispanic populations remain limited. We aimed to evaluate outcomes of R-mini-CHOP versus R-CHOP in elderly patients and to explore potential differences by ethnicity. Methods: Single-center retrospective analysis of adult patients older than 70 years with DLBCL and high-grade FL, treated between January 2014 and June 2025. Clinical characteristics, treatment responses, and survival outcomes were analyzed. The overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method. Results: A total of 136 patients were included (72 R-mini-CHOP; 64 R-CHOP). Patients receiving R-mini-CHOP were older (median 82 vs. 74 years) and had higher-risk features. Overall response rates were 88.7% and 92.6% in the R-mini-CHOP and R-CHOP groups, respectively. Two-year OS was 79.3% for R-mini-CHOP and 76.7% for R-CHOP. Median OS and PFS were not reached in either group. Elevated lactate dehydrogenase (LDH) was associated with an inferior response. We identified a trend toward better response with R-CHOP in Hispanic patients, although this was not statistically significant. Conclusions: In this real-world cohort, R-mini-CHOP achieved response and survival outcomes comparable to R-CHOP despite worse baseline characteristics. These findings support the use of dose-attenuated therapy in frail and elderly patients and suggest that equitable access to care may mitigate ethnic disparities in outcomes. Full article
(This article belongs to the Special Issue Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL))
►▼ Show Figures

Figure 1

9 pages, 1766 KB  
Article
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial
by Erel Joffe, Anita Kumar, Joseph M. Tuscano, Alison J. Moskowitz, Colette Owens, Ariela Noy, Maria Lia Palomba, Andrew D. Zelenetz, Andy Ni, Elad Sharon and Santosha Vardhana
Cancers 2026, 18(2), 284; https://doi.org/10.3390/cancers18020284 - 16 Jan 2026
Viewed by 863
Abstract
Introduction: Immune evasion through inhibition of effector T cells is a key survival mechanism of lymphoma cells. We hypothesized that reinstating effector T cell activity through concurrent inhibition of the PD1/PD-L1 axis and of Treg activity will result in a synergistic anti-tumor [...] Read more.
Introduction: Immune evasion through inhibition of effector T cells is a key survival mechanism of lymphoma cells. We hypothesized that reinstating effector T cell activity through concurrent inhibition of the PD1/PD-L1 axis and of Treg activity will result in a synergistic anti-tumor effect with an acceptable toxicity profile. Methods: Phase I multi-institutional NCI-ETCTN trial aimed to evaluate the safety and tolerability of the combination of mogamulizumab and pembrolizumab in relapsed or refractory non-Hodgkin lymphoma. The study used a 3 + 3 design. Treatment consisted of mogamulizumab 1 mg/kg on days 1, 8, and 15 of cycle 1, followed by 1.5 mg/kg on day 1 of each subsequent 21-day cycle in combination with pembrolizumab 200 mg on day 1 of each cycle. A de-escalation level was defined as a 50% reduction in the dose of mogamulizumab (registered in clinicaltrials.gov NCT03309878). Results: The study was discontinued early, after treating seven patients (two angioimmunoblastic T cell lymphoma, four transformed follicular lymphoma, and one diffuse large B cell lymphoma of germinal center subtype) for concerns of futility and non-tolerability. Only two patients completed the first two cycles of treatment. Three patients presented with an early progression and three withdrew consent in the setting of general deterioration with clinically suspected progression. All six patients expired shortly after withdrawal from the study. The remaining patient experienced stress cardiomyopathy during the third cycle and was taken off the study. Discussion: In striking difference to the observation in solid malignancies, the combination of mogamulizumab with pembrolizumab was associated with low tolerability and suspected hyper-progression in patients with lymphoma. Full article
(This article belongs to the Special Issue Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop